Scangos' new biotech tackling infectious disease

Deals with Alnylam and Visterra help Vir build out its pipeline.

By Jacob Bell • Oct. 19, 2017

Anthem leaves Express Scripts behind to roll out its own PBM

Named IngenioRx, the new pharma middleman is scheduled to debut in 2020.

By Jacob Bell • Oct. 18, 2017

Lilly taps CureVac for mRNA cancer drugs

The deal, worth almost $2 billion all told, validates CureVac's mRNA technology. 

By Lisa LaMotta • Oct. 18, 2017

Biopharma, medical M&A activity slows in 2017: report

Despite some big ticket transactions, global deal count and value have ticked down so far this year, according to a Mergermarket analysis. 

By Lisa LaMotta • Oct. 17, 2017

Amneal, Impax combine amid generics crunch

Together, the two companies will rank as the fifth-largest generics maker in the U.S. by gross revenue. 

By Ned Pagliarulo • Oct. 17, 2017

Financial woes trigger layoffs at Biostage

After a private placement deal went south, Biostage said it would cut 70% of staff in a move to stay solvent as it evaluates its options. 

By Suzanne Elvidge • Oct. 16, 2017

Roche kicks antibiotic development into Warp Drive

Through a deal with Warp Drive Bio, the Swiss drugmaker is looking to advance novel drugs at a time when antibiotic resistance is raising serious alarms.

By Jacob Bell • Oct. 16, 2017

Prescribed Reading: A week of game-changers in pharma

A new gene therapy is poised to hit the market; one dose of Anaptysbio's drug is all it took to clear some patients' skin; and a late-stage failure is hurting Lilly's oncology prospects.

By Lisa LaMotta • Oct. 13, 2017

SINE of the times: Karyopharm taps Ono for Asian market

The regional deal gives Ono the rights to Karyopharm's lead asset Selinexor and other cancer assets in certain parts of the world. 

By Suzanne Elvidge • Oct. 13, 2017

Merck invests in diabetes through KalVista deal

By taking a stake in KalVista, the big pharma aims to buffer its diabetes franchise with related therapies. 

By Lisa LaMotta • Oct. 11, 2017

Express Scripts drops $3.6B for healthcare management company

The PBM said this latest acquisition furthers its "goal of becoming the nation's leading patient benefit manager."

By Jacob Bell • Oct. 10, 2017

Pfizer mulls sale of consumer health business

A potential sale of the unit, which includes brands like Advil and Centrum, would allow Pfizer to focus resources on its higher-earning pharma division. 

By Lisa LaMotta • Oct. 10, 2017

AbbVie solidifies its I/O pipeline with Turnstone deal

A new agreement hands AbbVie the option to exclusively license up to three oncolytic viral immunotherapies.

By Jacob Bell • Oct. 10, 2017

Prescribed Reading: DMD, MS and other acronyms

Another DMD drug struggles to get closer to market, a blockbuster MS drug now faces multiple generic competitors, and a deal is inked to increase competition in the Tyk2 inhibitor space. 

By Lisa LaMotta • Oct. 6, 2017

Lonza snatches Shire facility as biologics manufacturing rakes in returns

The drug developer expects the new site will complement operations from another mammalian manufacturing plant in the U.K.

By Jacob Bell • Oct. 5, 2017

Amgen digs deeper in I/O with CytomX deal

More than a billion dollars in milestone payments is on the line as the drugmakers work on developing therapies using CytomX's Probody technology.

By Jacob Bell • Oct. 4, 2017

Celgene snaps up Nimbus assets in immunology deal

The deal gives the big biotech access to Nimbus' deep computational expertise and options to programs from the alliance.

By Suzanne Elvidge • Oct. 4, 2017

Endocyte shares shoot up on prostate cancer pact

The Indiana biopharma aims to pivot from R&D setbacks with a licensing deal for a new lead candidate.

By Suzanne Elvidge • Oct. 3, 2017

In RARE news, Dimension dumps Regenxbio for better offer

Ultragenyx's superior offer has trumped the previously announced deal for the gene therapy developer. 

By Suzanne Elvidge • Oct. 3, 2017

Prescribed Reading: No such thing as unicorns

Both closely watched Axovant and Intarcia had major setbacks this week, despite high hopes that their therapies would be game-changers. 

By Lisa LaMotta • Sept. 29, 2017

Arcturus to go public through merger with Alcobra

Combining with Alcobra will give currently private Arcturus access to public markets, while adding cash for development of its RNA-focused pipeline. 

By Suzanne Elvidge • Sept. 29, 2017

NewLink inks deal with AstraZeneca to test Imfinzi combo

IDO inhibitors like NewLink's indoximod are seen as a potentially fruitful pairing for PD-L1 inhibitors.   

By Suzanne Elvidge • Sept. 27, 2017

Prescribed Reading: Consolidation, clinical holds and landmark results

The FDA continues its clinical hold spree for PD-1/L1s, consolidation is rampant in the CDMO space and RNAi may become a reality very soon. 

By Lisa LaMotta • Sept. 22, 2017

Cellectar, Onconova partner on cancer drug conjugates

An early-stage collaboration could boost the two small-cap biotechs' pipelines.

By Suzanne Elvidge • Sept. 22, 2017

Taiho taps Arcus in latest I/O deal

The two biotechs have inked a development and commercialization agreement for immuno-oncology assets in Asia. 

By Suzanne Elvidge • Sept. 21, 2017